Skip to content
10-K

Annual Report

MoonLake Immunotherapeutics MLTX

0001821586-26-000002

← back to feed
Filed
Feb 25, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 64.46M sh
Shares Diluted FY 2025 · Dec 31, 2024 62.87M sh
Shares Diluted FY 2025 · Dec 31, 2023 49.12M sh
Capex FY 2025 · Dec 31, 2025 $35K
Capex restated FY 2025 · Dec 31, 2024 $520K
Capex restated FY 2025 · Dec 31, 2023 $284K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$196.01M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$116.59M
Operating Cash Flow restated FY 2025 · Dec 31, 2023 −$42.78M
Long Term Debt FY 2025 · Dec 31, 2025 $74.1M
Long Term Debt FY 2025 · Dec 31, 2024 $0
Cash And Equivalents FY 2025 · Dec 31, 2025 $334.52M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $180.43M
Stockholders Equity FY 2025 · Dec 31, 2025 $304.48M
Stockholders Equity restated FY 2025 · Dec 31, 2024 $446.83M
Current Liabilities FY 2025 · Dec 31, 2025 $45.48M
Current Liabilities restated FY 2025 · Dec 31, 2024 $22.46M
Total Liabilities FY 2025 · Dec 31, 2025 $119.95M
Total Liabilities restated FY 2025 · Dec 31, 2024 $24.54M
Current Assets FY 2025 · Dec 31, 2025 $421.69M
Current Assets restated FY 2025 · Dec 31, 2024 $474.29M
Total Assets FY 2025 · Dec 31, 2025 $424.43M
Total Assets restated FY 2025 · Dec 31, 2024 $477.93M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.53
Eps Diluted FY 2025 · Dec 31, 2024 −$1.89
Eps Diluted FY 2025 · Dec 31, 2023 −$0.73
Eps Basic FY 2025 · Dec 31, 2025 −$3.53
Eps Basic FY 2025 · Dec 31, 2024 −$1.89
Eps Basic FY 2025 · Dec 31, 2023 −$0.73
Sga Expense FY 2025 · Dec 31, 2025 $41.97M
Sga Expense restated FY 2025 · Dec 31, 2024 $30.32M
Sga Expense restated FY 2025 · Dec 31, 2023 $22.32M
Rd Expense FY 2025 · Dec 31, 2025 $202.86M
Rd Expense restated FY 2025 · Dec 31, 2024 $112.77M
Rd Expense restated FY 2025 · Dec 31, 2023 $31.8M
Net Income FY 2025 · Dec 31, 2025 −$227.32M
Net Income restated FY 2025 · Dec 31, 2024 −$118.94M
Net Income restated FY 2025 · Dec 31, 2023 −$36.01M
Operating Income FY 2025 · Dec 31, 2025 −$244.83M
Operating Income restated FY 2025 · Dec 31, 2024 −$143.09M
Operating Income restated FY 2025 · Dec 31, 2023 −$54.12M